» Articles » PMID: 9435795

[Cytotoxicity and Interaction of Amsacrine Derivatives with Topoisomerase II: Role of the 1' Substitute on the Aniline Nucleus]

Overview
Journal Bull Cancer
Publisher Elsevier
Specialty Oncology
Date 1998 Jan 22
PMID 9435795
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Amsacrine is an intercalating planar polycyclic aromatic molecule that displays antitumor activity. The cytotoxicity of this compound is related to its interaction with topoisomerase II. The substituent at position 1' on the aniline is thought to be essential to the formation of the topoisomerase II-DNA cleavable complex and hence the cytotoxicity of the drug. The influence of three substituents at position 1' on the modulation of the activity of topoisomerase II was investigated. The following observations emerge from our structure-activity relationship study: i) the effects of the drugs on topoisomerase II-mediated DNA cleavage in vitro are correlated with the results of the cytotoxicity assays performed with cells sensitive (DC-3F) and resistant to topoisomerase II inhibitors (DC-3F/9-OH-E); ii) depending on the nature of the 1' substituent of the drugs, the restoration of a normal topoisomerase II alpha catalytic activity in resistant DC-3F/9-OH-E cells transfected with a plasmid carrying a wild type topoisomerase II alpha cDNA (hTOP2) either does not modify the susceptibility of the cells to the drug or partially reverse the resistance phenotype. The molecular and cellular studies reveal that topoisomerase II alpha is implicated in the cytotoxicity of amsacrine and confirm that the substituent at position 1' on the anilino ring of amsacrine governs the interaction with topoisomerase II.

Citing Articles

Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion.

Luthra P, Aguirre S, Yen B, Pietzsch C, Sanchez-Aparicio M, Tigabu B mBio. 2017; 8(2).

PMID: 28377530 PMC: 5380843. DOI: 10.1128/mBio.00368-17.


Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.

Ryan E, Blake A, Benoit A, David M, Robert A Invest New Drugs. 2012; 31(2):285-92.

PMID: 22821172 DOI: 10.1007/s10637-012-9854-2.


Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.

Raza A, Jacobson B, Benoit A, Patel M, Jay-Dixon J, Hiasa H Invest New Drugs. 2011; 30(4):1443-8.

PMID: 21789510 DOI: 10.1007/s10637-011-9720-7.